Geron Corp
GERN1.320USD
+0.050+3.94%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
841.96MMarket Cap
LossP/E TTM
More Details of Geron Corp Company
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Company Info
Ticker SymbolGERN
Company nameGeron Corp
IPO dateJul 31, 1996
CEOMr. Harout Semerjian
Number of employees229
Security typeOrdinary Share
Fiscal year-endJul 31
Address919 East Hillsdale Boulevard
CityFOSTER CITY
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94404
Phone16504737700
Websitehttps://www.geron.com/
Ticker SymbolGERN
IPO dateJul 31, 1996
CEOMr. Harout Semerjian
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Robert J. (Bob) Spiegel, M.D.
Dr. Robert J. (Bob) Spiegel, M.D.
Independent Director
Independent Director
182.84K
+3.12%
Dr. Susan M. Molineaux, Ph.D.
Dr. Susan M. Molineaux, Ph.D.
Independent Director
Independent Director
130.53K
--
Mr. Jim Ziegler
Mr. Jim Ziegler
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
100.00K
--
Dr. Andrew J. (Andy) Grethlein, Ph.D.
Dr. Andrew J. (Andy) Grethlein, Ph.D.
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
2.27K
--
Mr. Harout Semerjian
Mr. Harout Semerjian
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Elizabeth G. O'Farrell
Ms. Elizabeth G. O'Farrell
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
--
--
Ms. Shannon T. Odam
Ms. Shannon T. Odam
Chief People Officer, Senior Vice President
Chief People Officer, Senior Vice President
--
--
Mr. John F. Mcdonald
Mr. John F. Mcdonald
Independent Director
Independent Director
--
--
Dr. Faye Feller, M.D.
Dr. Faye Feller, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
-100.00%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Robert J. (Bob) Spiegel, M.D.
Dr. Robert J. (Bob) Spiegel, M.D.
Independent Director
Independent Director
182.84K
+3.12%
Dr. Susan M. Molineaux, Ph.D.
Dr. Susan M. Molineaux, Ph.D.
Independent Director
Independent Director
130.53K
--
Mr. Jim Ziegler
Mr. Jim Ziegler
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
100.00K
--
Dr. Andrew J. (Andy) Grethlein, Ph.D.
Dr. Andrew J. (Andy) Grethlein, Ph.D.
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
2.27K
--
Mr. Harout Semerjian
Mr. Harout Semerjian
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Elizabeth G. O'Farrell
Ms. Elizabeth G. O'Farrell
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
9.46%
BlackRock Institutional Trust Company, N.A.
6.80%
Deep Track Capital LP
6.74%
The Vanguard Group, Inc.
5.56%
Vivo Capital, LLC
4.27%
Other
67.17%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
9.46%
BlackRock Institutional Trust Company, N.A.
6.80%
Deep Track Capital LP
6.74%
The Vanguard Group, Inc.
5.56%
Vivo Capital, LLC
4.27%
Other
67.17%
Shareholder Types
Shareholders
Proportion
Investment Advisor
22.24%
Hedge Fund
21.78%
Investment Advisor/Hedge Fund
18.83%
Venture Capital
13.75%
Research Firm
4.70%
Bank and Trust
0.34%
Pension Fund
0.21%
Private Equity
0.11%
Individual Investor
0.11%
Other
17.93%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
556
522.02M
81.82%
-109.82M
2025Q1
562
519.35M
81.62%
-112.90M
2024Q4
542
496.89M
78.04%
-104.32M
2024Q3
507
516.63M
85.72%
-55.02M
2024Q2
483
472.64M
79.70%
-11.19M
2024Q1
446
440.86M
75.14%
+14.56M
2023Q4
419
400.36M
73.45%
-3.49M
2023Q3
411
378.82M
69.84%
+5.68M
2023Q2
402
349.17M
68.60%
+5.31M
2023Q1
380
329.50M
64.83%
+90.65M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
60.38M
9.48%
+30.37M
+101.20%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
43.06M
6.76%
-1.01M
-2.29%
Mar 31, 2025
Deep Track Capital LP
38.18M
5.99%
+34.16M
+851.72%
Mar 31, 2025
The Vanguard Group, Inc.
34.02M
5.34%
+608.03K
+1.82%
Mar 31, 2025
Vivo Capital, LLC
27.23M
4.27%
--
--
Mar 31, 2025
Vestal Point Capital, LP
22.01M
3.46%
+11.01M
+100.05%
Mar 31, 2025
State Street Global Advisors (US)
23.91M
3.75%
-3.25M
-11.95%
Mar 31, 2025
ClearBridge Investments, LLC
8.69M
1.36%
+8.69M
--
Mar 31, 2025
Geode Capital Management, L.L.C.
13.57M
2.13%
+426.08K
+3.24%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
